Secukinumab Shows Benefit for Hidradenitis Suppurativa at 1

Currently, the tumor necrosis factor inhibitor adalimumab is the only biologic therapy approved for the treatment of moderate to severe hidradenitis suppurativa.

Related Keywords

Boston , Massachusetts , United States , Washington , Adam Friedman , Alexab Kimball , European Academy Of Dermatology , Pfizer , George Washington University , Beth Israel Deaconess Medical Center , Harvard Medical School , Novartis , European Academy , Global Assessment , Skin Pain Numeric Rating Scale , Skin And Soft Tissue Infection , Hidradenitis Suppurativa , Biologic Therapy , Tumor , Europe , European , Imbalance , Spain , Otolaryngology , Nt Ears , Nose , Throat , Clinical Research , Clinical Trials , Linical Studies , Interleukins , Match , Match Day , Watch Application , Atch Medical Students , Common Cold , Cute Nasopharyngitis , Pain Management , Psoriasis , Headache , Healthcare And ,